Conmed (CNMD) Q3 2026 earnings review
Conmed's overseas sales jump, but its US business stalls
Conmed, a maker of surgical tools and orthopedic implants, leaned on overseas demand while its US business stalled. Underlying sales from ongoing product lines grew 7% in constant currency as international revenue jumped 14%, making up for flat US sales. Chief executive Patrick Beyer nudged the full-year profit outlook higher after third-quarter earnings beat the company's plan, but he trimmed the top end of the full-year sales growth target.
| Sales from ongoing businesses (constant currency) | +6.7% planned 6.4–7.6% |
|---|---|
| Reported revenue | $335.6M -0.7% from a year ago |
| Profit per share, excluding one-offs | $1.04 -3.2% from a year ago |
| Full-year underlying sales outlook | Cut top end now 5.0–5.5% (was 5.0–6.0%) |
⚖️ Verdict: 🔴 Bearish
The story got worse because Conmed trimmed its full-year underlying sales ceiling for a second straight quarter while US orthopedic revenue shrank 2%. Fixing factory backorders was supposed to let the US sales team win back lost hospital accounts, yet domestic orthopedic sales went backward and US equipment installations fell. The bright spot: General Surgery accelerated to 6% underlying growth, and outside consulting bills finally dropped below $4 million.
The question now is whether General Surgery's rebound means AirSeal is holding its own on new surgical robots, or whether booming overseas sales are masking domestic share losses across both divisions. If AirSeal is holding up and US hospitals are just slow to switch back, growth will step up once the gastrointestinal exit clears next year; if US accounts are gone for good, growth will stay near the lowered 5% floor. Fourth-quarter US sales and the initial 2027 outlook will settle it.
🐂 Bull Case
General Surgery Accelerated on Overseas Demand
General Surgery is Conmed's largest division, selling tools for minimally invasive operations. Chief executive Patrick Beyer said third-quarter growth included "balanced contributions from both our Orthopedic and General Surgery product lines", driven by AirSeal, its system that maintains abdominal pressure during keyhole surgery, and Buffalo Filter, its surgical smoke evacuator.
Sales from ongoing General Surgery products rose 6.4% in constant currency, up from 5.3% in the second quarter. In July, Conmed also announced that AirSeal is now "indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform". International buyers carried the division, as overseas underlying sales jumped 15.5% while US underlying sales rose 1.9%.
This acceleration matters because General Surgery houses AirSeal, which fell short of management's plan last quarter. Faster division growth shows that newer surgical robots are not pushing AirSeal out of operating rooms as fast as feared, at least outside the United States.
What to watch: General Surgery underlying growth in the fourth quarter. Another reading above 6% would show the division can keep growing even as surgical robot fleets upgrade.
Factory Consulting Costs Dropped Below $5 Million
For nearly two years Conmed has paid outside consultants to fix its manufacturing and supply chain, excluding those bills from its preferred profit figures. Last quarter management said the company had moved past recovery into routine improvements, which meant the consulting bills should start to fade.
In the third quarter, operational optimization charges fell to $3.2 million, down from $7.1 million in the second quarter and $9.2 million a year ago. With last year's $19.7 million inventory write-off also gone, cost of sales fell from 50.8% of revenue to 43.6%, lifting reported gross margin by 7.2 percentage points to 56.4%. That narrowed the gap between reported profit and profit excluding one-offs to $0.38 per share, down from $0.61 in the second quarter.
What to watch: operational optimization charges in the fourth-quarter reconciliation table. A reading near zero would confirm the consulting project is over and let reported profit catch up with adjusted profit.
Positives this quarter didn't test
Two standing drivers from earlier quarters received no new figures in the third-quarter earnings release.
- State laws requiring operating rooms to clear surgical smoke: 22 US states had passed laws covering 57% of the population as of last quarter, with compliance deadlines starting in July 2027; the conference call or filing will show if more states joined.
- Debt reduction and board refreshment: leverage stood at 2.9 times EBITDA after the June debt refinancing and two medical-technology directors joined in July; the quarterly filing's balance sheet will show third-quarter debt and cash.
🐻 Bear Case
Conmed Trimmed Its Full-Year Sales Plan Again
"Our third quarter organic, constant currency net sales growth was consistent with our expectations and our adjusted diluted EPS exceeded them," Beyer said. Conmed measures underlying sales in constant currency and excludes the gastrointestinal (GI) product lines it exited in the first half of the year.
Despite Beyer's upbeat framing, the surgical device maker lowered the top end of its full-year underlying sales growth plan for a second straight quarter, to 5.0%–5.5% from 5.0%–6.0% in July and 5.0%–6.5% in April. Third-quarter underlying sales grew 6.7%, below the 7.0% middle of its quarterly plan. Sales of capital equipment — machines installed in hospitals that pull through later sales of single-use supplies — grew 2.1% in constant currency, down from 7.6% in the second quarter, as US capital sales fell 7.3%.
By our math, the new full-year outlook implies fourth-quarter underlying growth of about 5.9%, slower than both the second and third quarters. Slower machine installations today also mean fewer recurring supply sales over the next two quarters.
What to watch: initial 2027 underlying sales growth outlook when fourth-quarter results arrive in January. A target midpoint below 6% would confirm that slower hospital equipment buying is holding back next year's sales.
US Orthopedic Sales Turned Negative
Orthopedic Surgery sells joint-repair devices and BioBrace, a soft-tissue implant that reinforces torn tendons and ligaments. After fixing the warehouse and supply bottlenecks that cost it US customers over the past two years, Conmed said its sales force was back on the attack to win back hospital accounts.
Instead of rebounding, US orthopedic sales fell 1.7% from a year ago in the third quarter, after flat performance in the second quarter. Across the whole company, underlying US sales rose 0.8%, down from 2.5% in the second quarter and 2.8% in the first. Total orthopedic underlying growth reached 7.2% only because international orthopedic sales jumped 12.7% in constant currency.
This split matters because fixed factories cannot drive growth if US surgeons stick with the rival products they switched to during Conmed's supply shortages.
What to watch: domestic orthopedic revenue growth in the fourth quarter, when the prior-year comparison is toughest. Another decline would show Conmed has lost those US hospital accounts permanently.
Higher Interest Costs Cut Into Fourth-Quarter Profit
In June, Conmed refinanced its low-interest convertible notes with higher-rate bank loans, lifting its annual interest bill. In the second quarter, a one-time $0.21 per share tariff refund hid that extra interest cost and boosted profit.
With no refund in the third quarter, the financing drag showed up in the bottom line. Operating profit excluding one-offs rose 0.7% to $51.5 million as operating margin edged up 0.3 percentage points to 15.4%. However, adjusted interest expense jumped 66.3% from a year ago to $10.5 million, or 3.1% of revenue versus 1.9% last year, pushing profit per share excluding one-offs down 3.2% to $1.04.
By our math, the updated full-year plan leaves fourth-quarter profit per share at $1.23–1.30, down 11.5% from last year's $1.43 at the middle of the range because interest and tariffs weigh on earnings.
What to watch: 2027 interest expense and tariff cost estimates on the fourth-quarter call. Those figures will show how much of this year's financing drag carries into next year.
Risks this quarter didn't answer
Four standing concerns could not be tested from the third-quarter earnings release alone.
- AirSeal attachment on new robots: management named AirSeal a growth driver and noted the July da Vinci 5 cannula approval, but gave no growth rate or robot attachment rate for a fifth straight quarter; the conference call Q&A is the next place to check.
- Free cash flow and inventory: the release includes no cash flow statement or balance sheet to test whether second-half cash generation can reach the $115 million full-year target; the quarterly 10-Q filing will show both.
- June 2027 convertible note maturity: $154 million remains due next June, with no update on revolver borrowings or cash balances until the 10-Q filing arrives.
- Finance chief transition: John Gallagher completed his first quarter as chief financial officer while his predecessor remains an adviser through November; the fourth-quarter report will be his first solo close.
💲 Other KPIs
Fell 3.0% from 31.05 million a year ago, after Conmed suspended its dividend late last year and spent $43.7 million buying back shares in the first half. The count ticked up slightly from 30.12 million in the second quarter, suggesting few or no buybacks in the third quarter, though the lower share count still cushioned per-share profit.
Down 1.2% as reported and 1.3% in constant currency from a year ago, making up 85.1% of Conmed's total revenue. Single-use products are disposable supplies used once per surgery. The reported decline reflects the exit from gastrointestinal disposables, which dragged domestic single-use sales down 11.5% while international single-use sales grew 13.0% in constant currency.
Rose 3.4% from $65.6 million a year ago, lifting the adjusted EBITDA margin by 0.8 percentage points to 20.2% of revenue. Adjusted EBITDA is earnings before interest, taxes, depreciation, amortization, stock compensation and one-off charges. Unlike per-share profit, it sits above the interest line, so it grew even as higher debt costs weighed on net earnings.
🔮 Guidance
Cut. The middle of the full-year reported sales range moved down $2.5 million to $1,363 million, or a 0.9% decline from last year, as a slightly worse currency drag (-0.7% versus -0.5% previously) and a lower top end outweighed a $2 million lift to the bottom. By our math, that leaves fourth-quarter reported sales at $364–370 million, down 1.7% from a year ago at the middle of the range. Earlier moves this year were +$2.5M and +$3.0M before this -$2.5M trim.
Cut. Conmed trimmed the top of its underlying constant-currency growth target by 0.5 percentage points for a second quarter in a row, lowering the middle of the plan from 5.5% to 5.25%. After 5.0% underlying growth across the first nine months, the full-year outlook implies fourth-quarter underlying growth of about 5.9% by our math, down from 6.7% in the third quarter against a tough 7.1% comparison a year ago.
Raised. The surgical supplier lifted the bottom of its full-year adjusted profit range by six cents and the top by a penny, moving the middle up $0.035 to $4.575 per share (down 0.3% from last year). That passes through the third-quarter beat. By our math, the outlook leaves fourth-quarter profit per share at $1.23–1.30, an 11.5% drop from last year's $1.43 at the middle of the range as higher interest and tariffs bite.
❓ Key Questions
How fast did AirSeal grow, and did DV5 attachment rise?
Beyer credited AirSeal for General Surgery's acceleration and noted July's approval for Intuitive's da Vinci 5 hex cannulas, but gave no numbers. Without AirSeal's growth rate or its attachment rate on da Vinci 5 robots, investors cannot tell if overseas sales are hiding a US slowdown.
Why did US orthopedic sales shrink after the supply fix?
Management said service levels and backorders are back to normal, yet domestic orthopedic sales fell 1.7% after a flat second quarter. Did Conmed lose hospital contracts during the outage, or did pricing and procedure volumes slow in the third quarter?
Why did US capital equipment sales drop 7.3%?
Total capital equipment growth slowed to 2.1% in constant currency because domestic capital revenue fell 7.3%. Because machine installations pull through single-use supply sales one to two quarters later, we need to know whether hospital budgets tightened or large orders slipped into Q4.
Did third-quarter cash flow and inventory improve toward the target?
First-half operating cash flow fell 28% to $50.6 million on high inventory, forcing a cut to the full-year free cash flow outlook to $115 million. Because the release omits the cash flow statement and balance sheet, management needs to quantify Q3 cash generation.
How much has the factory consulting project saved so far?
Operational optimization consulting charges dropped to $3.2 million from $7.1 million last quarter, after costing more than $40 million since late 2024. Management targeted at least $20 million in annual savings from this work but has not yet stated how much is in the margin.